NASDAQ:RNXT
RenovoRx, Inc.
RenovoRx, Inc.'s revenue grew 2511.6% in fiscal 2025 to $1.1M while operating margin rose to −1114.0%. Free cash flow was −$11.0M, −977.3% of revenue, and the diluted share count rose 58.6%.Summary generated from RenovoRx, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.1M
Revenue growth+2511.6%
Revenue, 5-yr CAGRn/a
Gross margin70.9%
Operating margin−1114.0%
Net margin−994.5%
ROICn/a
Return on equity−225.6%
Debt / equityn/a
Free cash flow−$11.0M
FCF margin−977.3%
Share count change+58.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | 0 | 1 |
| Operating income | −6 | −10 | −11 | −11 | −13 |
| Net income | −6 | −10 | −10 | −9 | −11 |
| Free cash flow | n/a | n/a | n/a | −9 | −11 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Oct 2, 2026 - 8-KOther events
Aug 20, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-K/AAmended results of operations and financial condition
Aug 13, 2026 - 8-KCurrent report
Aug 12, 2026 - 8-KOther events
Aug 4, 2026 - 8-KNotice of delisting or listing-rule failure
Jul 2, 2026